Exploring telitacicept in a patient with pemphigus vulgaris

Our case demonstrates significant improvement in autoantibody levels and clinical outcomes, suggesting that telitacicept could be an alternative treatment for patients with mild pemphigus [Pemphigus Disease Area Index (PDAI) ＞9] who are not recommended for treatment with rituximab (PDAI ＜15), and especially for those unresponsive to conventional treatments or with treatment-resistant scalp lesions in pemphigus.